The comparison of isavuconazole and voriconazole as oral sequential therapy for invasive aspergillosis in patients with hematological malignancies
Objective:To investigate and analyze the efficacy and safety of oral isavuconazole and voriconazole as oral sequential therapy for invasive aspergillosis in patients with hematological diseases.Methods:The clinical data of 45 patients diagnosed as invasive aspergillosis and treated with voriconazole intravenously in the stem cell transplantation center of Hematology Hospital of Chinese Academy of Medical Sciences from November 2019 to January 2023 were retrospectively analyzed.Among them,22 patients were treated with oral sequential therapy of voriconazole tablets and 23 patients were treated with oral sequential therapy of isavuconazole capsules.Results:Only 1 patient in the isavuconazole group was evaluated as ineffective,and 17 of the remaining 22 patients who re-sponded to treatment were evaluated as complete remission.The overall remission rate was 95.65％(22/23),and the complete remission rate was 73.91％(17/23).The overall remission rate of voriconazole treatment group was 86.36％(19/22),and the complete remission rate was 50.00％(11/22).There was no significant difference in the remission rate between the two groups.Additionally,patients in both groups were well tolerated.Conclusion:Isa-vuconazole has similar efficacy and good safety as oral sequential therapy compared to voriconazole tablets for inva-sive aspergillosis in patients with hematological diseases.
NETL
NSTL
万方数据
